Pancreatic Cancer

Positive results from a phase 2 study of a three-drug regimen to treat biliary tract cancer paved the way for the first randomized phase 3 study of its kind in the U.S., led by Rachna Shroff, MD, MS.

Deirdre J. Cohen, MD, MS, has been appointed director of the gastrointestinal oncology program at Mount Sinai Health System.

Our understanding of pancreatic cancer biology is advancing rapidly.

Henry A. Pitt, MD, has been named chief of oncologic quality at Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital.

The FDA granted orphan drug designation to KN046 for the treatment of patients with thymic epithelial tumors, according to a manufacturer-issued press release.

Recent-onset diabetes accompanied by weight loss appeared to be associated with a substantially higher risk for developing pancreatic cancer, according to results of a retrospective cohort study published in JAMA Oncology.

The U.S. Preventive Services Task Force has issued a draft recommendation that lowers the age to begin lung cancer screening in individuals with a history of smoking. It was the top story in hematology/oncology last week.

A liquid biopsy has shown promise for the early detection and staging of pancreatic ductal adenocarcinoma.

The FDA granted fast track designation to liposomal irinotecan as part of a first-line combination for the treatment of adults with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma.

NantKwest and ImmunityBio have partnered on a phase 2 trial to examine the efficacy and safety of a chemoimmunotherapy regimen for treatment of metastatic or locally advanced pancreatic cancer.